{"ticker": {"uuid": "00c0ba0e-839d-4b83-8101-db908d22fc0b", "symbol": "MLTX", "name": "MoonLake Immunotherapeutics", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNEtNMTRHMHZBb2RadXVlOWhUTDlidk8wMG1udVBmWVFDSHdVOGttVy00VWxqdlBjV21ZQ1dFVDQ5OWJFYklWRWZiWjZpb3E0SzdqUzBDWDVTSWlHY3RRZzFGbTAwVTJ1WEtXWEZlZnY2U1VNcHhLREhfS1NtYUNzU2gxcTZTaEN3dkROYzByWkZjakN6aF8yZVljdzhaVTl0UjR3VTc3Skc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:47:09+00:00", "published_display": "15 Jul 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise", "summary": "MoonLake Immunotherapeutics announced that underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares as part of a previously announced public offering. This exercise, which closed on July 14, 2026, generated an additional $30.0 million ", "url": "https://www.stocktitan.net/sec-filings/MLTX/8-k-moon-lake-immunotherapeutics-reports-material-event-858ab2e59057.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:11:17", "published_display": "15 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of MoonLake Immunotherapeutics (MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxQT09MN2NQNDh1WFBrUmVUMkJ2b2dQYnRYRllqcDBnYzMwYzNmbjVqNEI1RXVCTmlxTWp4ejlaZk90aE9MMVFpcl9oWVVJTmtlTDZWLUpGYURmelhOOE5HOUJGc3JSTkRyd19SeVk4TzVjdkxnbml5X21YeFVzWU9DWXU3Wk43YzZHTWtoTXIwdWY1WXFKRzc5MFl4ei1BTTltM0ctMDVPaktXeGFEMmVUYzBpdk9acGxqRVlFLTh0R0JSaUpGRUdKZzRtUDdzMGZjYmpMZ2F4eUJFdk9tRjd4U19fZjNOd2xQaUhNbTRrblowZEdtV3FPZmJqQXh3QQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T09:26:48+00:00", "published_display": "14 Jul 2026 09:26", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZkVHa3l5SEF6dW9vM1RCS1ZqckR5enZVMHRxWjVnR0FDTE52VUlKWW40RXVKa0xra2pTemlhbXBodjVUWFFMemJCRXRIWjVNZFkzUXNRQjJncHZRT1NCZUNiQkdnaWJGRndFY1RZLTZBLVdhVG5SSzhVdXFNbk9LWHlHenZKdjVGOHplX3VUdjdLSG50c29fcVJzWkN0SmwwQ0d0UldpbnQxUTQ3SVNyLXFBUU5LVDQ4TVg5Ui1lQTRoRWY4OVR6UlEzVkhGZmc?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T06:55:22+00:00", "published_display": "14 Jul 2026 06:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MoonLake Immunotherapeutics Insider Trading Activity", "summary": "MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 102,225 Class A ordinary shares in open market transactions on July 9 and 10, 2026. The sales, totaling approximately $2.05 million, were made under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, S", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-f1f6911c9177.html", "source_name": "Stock Titan", "published_at": "2026-07-13T19:42:00", "published_display": "13 Jul 2026 19:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Dip As Trump-Iran Tensions Lift Crude Oil Prices: Why MU, MRAM, MLTX, DRTS, ASTS Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNTHI0dUdheHljRkpJZlZiZURTX0x6TDAwZFNNdWVmUW0ya0tENzJYMkVjYkEwUGpGOW9TUkZRX2xma3ZGYy1xU2RqT1JKVjVaMUVVU1U0bmUtWFh0cVJUNUdoYjR5QUNybEVkVndCY2NNSUtfM1dUcUlQSFQwUVp4UXJWTWpMN1JsYTR2Nm5rRXJ4V08zSnFkdk1zcVNTMWVPdHdKUG1BaTZOa3JwdklSUGtZRUtYb0twUlEySlZhWHFFVHVldmt0S2FCMXQ3LTg?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T15:08:28+00:00", "published_display": "13 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan", "summary": "The CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX), Jorge Santos da Silva, sold 47,775 Class A ordinary shares at a weighted average price of $20.03 per share on July 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 202", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-7c16db97488b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T16:39:20", "published_display": "03 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics' CFO Sells 39K Shares", "summary": "", "url": "https://finance.yahoo.com/m/e2ea9480-3335-3987-851b-a172c41d9171/moonlake-immunotherapeutics%27.html", "source_name": "Motley Fool", "published_at": "2026-07-03T14:34:01+00:00", "published_display": "03 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX) \u2013 Recover Losses - Contact Levi & Korsinsky Before December 15, 2025", "summary": "A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made fals", "url": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-against-moonlake-immunotherapeutics-mltx-0", "source_name": "The National Law Review", "published_at": "2026-07-02T12:40:51", "published_display": "02 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026)", "summary": "MoonLake Immunotherapeutics (MLTX) has filed a Rule 144 notice indicating a proposed resale of 150,000 Class A Ordinary shares. The filing specifies a contemporaneous sale of these shares by Jorge Santos da Silva on April 10, 2026, for $2,787,000.00. The shares are listed on Nasd", "url": "https://www.stocktitan.net/sec-filings/MLTX/144-moon-lake-immunotherapeutics-sec-filing-be5d4a3abe72.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:11:22", "published_display": "01 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPai1ZcnNDYmk3WHFjS3ZHS2NzYmpHTzlWMjV0cV9lNk5XMmVVRE1ERGtLbFNHRUtBY3pzSEdJQnJnRnJJMmlKTG9OS2x3a0xpaHpJclRXVjRYTlFVeW4ycDIwUkhZMXlIZ0xLWVFNM3d3NWxsdDVDTjFCc2dDQVgycmxjVjAzd0RwQUZqN2h6QlJTWTVtQUtjRy1zR3FoYVBfTU1ISl9TMmpTTmdiNHBma1Bldw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake", "summary": "BVF group has updated its ownership disclosure in MoonLake Immunotherapeutics (MLTX) through an Amendment No. 6 to its Schedule 13D. The filing indicates that BVF-affiliated funds beneficially own 16,001,284 Class A ordinary shares, representing approximately 19.7% of MoonLake's ", "url": "https://www.stocktitan.net/sec-filings/MLTX/schedule-13d-a-moon-lake-immunotherapeutics-amended-major-shareholder-3ca86f17b419.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:09:32", "published_display": "30 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1IQjQwZm4wQlZjSUQyVlYzOWxMeGYxeTVmWFpTd3pfUjN3dGdRZ2txMDJ4aHN1QlRfMHByQXZYdXZYN1oxOUFuN2syVzdfa2lqSkwxaEdtRjRfMWJZanBxUjhnTzM?oc=5", "source_name": "ChartMill", "published_at": "2026-06-29T17:39:03+00:00", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab Push - Has The Bull Case Changed?", "summary": "MoonLake Immunotherapeutics (MLTX) recently raised $200 million through a follow-on equity offering to fund its sonelokimab program, particularly for the planned Biologics License Application (BLA) in hidradenitis suppurativa and pre-commercial activities. This capital raise, fol", "url": "https://www.sahmcapital.com/news/content/moonlake-immunotherapeutics-mltx-is-down-102-after-200m-follow-on-offering-to-fund-sonelokimab-push-has-the-bull-case-changed-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-29T17:09:05", "published_display": "29 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares", "summary": "MoonLake Immunotherapeutics (NASDAQ: MLTX) has successfully completed a $200 million public offering of its Class A shares. The offering involved legal advisory from Gibson, Dunn & Crutcher LLP and Walkers (Cayman) LLP for MoonLake, while Mintz, Levin, Cohn, Ferris, Glovsky, and ", "url": "https://globallegalchronicle.com/post-236054/", "source_name": "Global Legal Chronicle", "published_at": "2026-06-29T14:39:49", "published_display": "29 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (MLTX) for alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements about the purported superiority of it", "url": "https://natlawreview.com/press-releases/lost-money-moonlake-immunotherapeutics-mltx-join-class-action-december-15", "source_name": "The National Law Review", "published_at": "2026-06-28T17:10:20", "published_display": "28 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX)", "summary": "This article provides an overview of MoonLake Immunotherapeutics (NASDAQ: MLTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial information such as past earnings and revenue, upcoming earnings dat", "url": "https://www.tradingview.com/symbols/NASDAQ-MLTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:32", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United States - Mintz Advises On MoonLake Immunotherapeutics\u2019 $200 Million Public Offering", "summary": "Mintz advised the underwriters for MoonLake Immunotherapeutics' $200 million public offering of Class A ordinary shares. Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital served as joint bookrunning managers, with H.C. Wainwright & Co. and Clear Street as lead ", "url": "https://www.mondaq.com/pressrelease/200328/mintz-advises-on-moonlake-immunotherapeutics-%24200-million-public-offering", "source_name": "Mondaq", "published_at": "2026-06-26T03:41:09", "published_display": "26 Jun 2026 03:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (BOATS:MLTX)", "summary": "This article provides an overview of MoonLake Immunotherapeutics (MLTX) stock, including financial actuals and analyst estimates. It details the company's valuation metrics, past financial performance, future earnings projections, and historical stock prices. Key financial figure", "url": "https://www.tradingview.com/symbols/BOATS-MLTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:20", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (BIVA:MLTX/N)", "summary": "This article provides financial actuals and estimates for MoonLake Immunotherapeutics Class A (MLTX/N) traded on BIVA exchange, including market cap, earnings reports, revenue, and net income. It also details analysts' price targets, stock volatility, and employees. The company's", "url": "https://www.tradingview.com/symbols/BIVA-MLTX/N/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T00:41:09", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MLTX/N Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MoonLake Immunotherapeutics Class A (MLTX/N) stock, including analyst price targets, ratings, and financial metrics. It highlights that 14 analysts offer 1-year price forecasts, and outlines the company's past earnings, revenue, and market cap", "url": "https://www.tradingview.com/symbols/BIVA-MLTX/N/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:09", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWnlHUlBlazhib29ubDFMNEZBaDdFX1FZbVZhdjlGVGVSQVhVZGxKQ1ZhZDgwQjJZWjlVX3pGOHFKNzl5bjhUaWx3ZTYtSklNN3NkLTUzTzBVQzFRZnVISGp5OXBLVXVKd1JUN3BnQzdtTVFsa0gtbXk1U0h5Q1pwMllEQVlybFlDWkFkS2pxbG4teFFOUkpfeExaZjk4OWF2RF9Bb3ZwOFhsQk5ZNThNY1RObmU?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) launches $200M equity and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPM0RXWTJ5RjhqYmdHOUZVSGtYMmV0SEQ5SVlnQ1AxRGdVdXhBSVprcFVrd2lyak16cktmMEhRWjRiczhmLVlOWlVfblhYVDlHX2ZIaWl4RUFENzVWcE11cDVMRmpOSl9MUjR1NG1iZ1E2QXRfcl8tRFNYOGljZnVDRV9lWTctelNxMjd2UEFlOFo5c1NtVFlzTVI0dlpDQjhueGhmNFpYYldIYUd3NnNRbHdob1FjVnBG?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Proposed Public Offering", "summary": "MoonLake Immunotherapeutics has announced a proposed public offering of $150 million of its Class A ordinary shares, and potentially pre-funded warrants, to fund the development and commercialization of its investigational drug sonelokimab. The company also expects to grant under", "url": "https://uk.finance.yahoo.com/news/moonlake-immunotherapeutics-announces-proposed-public-200100398.html", "source_name": "Market source", "published_at": "2026-06-25T03:39:09", "published_display": "25 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-prices-200-million-073356678.html", "source_name": "MT Newswires", "published_at": "2026-06-24T07:33:56+00:00", "published_display": "24 Jun 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics prices $200M public offering to fund inflammatory disease drug development", "summary": "MoonLake Immunotherapeutics has priced a $200 million public offering, selling 9 million Class A shares at $20 each, along with pre-funded warrants. The funding is intended to advance the development and commercialization of sonelokimab, a drug for inflammatory diseases like hidr", "url": "https://pluang.com/en/news-feed/moonlake-immunotherapeutics-mengumumkan-penawaran-publik-200-juta-dolar", "source_name": "Pluang", "published_at": "2026-06-24T08:11:07", "published_display": "24 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why MoonLake Immunotherapeutics Stock Wilted on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVzJYVEJRTU9neURTNUVjTThmQzgwY0pyZnNaUFpQTmRpNzBLcnU0VWFDalp1VlhSRDhBNFBXa3V0R3FDUFBxZGlYV2ZOa29FcFNfMF9sNVdkR3NGaXQ0T1dUb252cXczT0NOWFZyZmEtY2JRZTJYaWxsbkNKQm5kSktBQlAzUjZEaTJFNHIzMHRKRDNqQXVPVw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) On Phase 3 Data While A 6x P B Valuation Looks Pricey", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) offers 9M shares at $20; 1M pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNRUZtTTBKUFhZM3I1cXJhZ2JuaFV2NGlKaXhDQ1FkNFQ4MTJpaDY4Vk1ZLUR0SXJKdXlIOWJYVHM5dGhWOTJscWhDTTJ4M3NEZVpqal9iOE56cFU2WTM4MDBUYm01RWgzOUVOUy0wdTAtZmNfQmU2Ni1ZRnJtS3JJSUxTYVhjT1N1TGRMMWJyUFNELWNoOENLbEZMdXlaaE5HblJ1SmtjZGZCZjVRa0piT19ZUnF1TFpmYVVWbmdhRkFDNEExWm5tSjBiaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants | MLTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQZGtHZlBqX09IR0xEYkREZXNKVjBFTE5GS01PejhSYkVCT0R5VkVvRDNsbFVEb01MY2JBNkZmeDluLXl6WHFrX0lIeGxqYk1JU01qQ1ljaHVGTWFWa090WWtSUnFScE0wQW5ERjYzU2V4Q250S1Y0MnIzdEhkX280czNFQ2xmeWFIekxDRnItd2huM29wZ3Y1SDdqaEtLQW4zWmZ5czdVZ2hKVDh5TDZiV2d0MmEyaW1rd3dhNVFMU0Z1ZGhFcndqY2lOcEkyMXRpeDFUQTBfbHVRN2dYMTk5VDBTOA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake seeks $200M to fund sonelokimab work", "summary": "MoonLake Immunotherapeutics has priced an upsized underwritten public offering to raise approximately $200 million in gross proceeds. The funds, combined with existing cash, are intended to finance the research, development, and potential commercialization of sonelokimab, a novel", "url": "https://www.stocktitan.net/news/MLTX/moon-lake-immunotherapeutics-announces-pricing-of-upsized-200-p76858wi6hqx.html", "source_name": "Stock Titan", "published_at": "2026-06-24T07:11:07", "published_display": "24 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics announces $150M public offering", "summary": "MoonLake Immunotherapeutics has announced a public offering aimed at raising $150 million. The company is involved in the biotechnology sector, focusing on immunotherapeutics. This offering is likely intended to fund ongoing research, clinical trials, or general corporate purpose", "url": "http://www.msn.com/en-us/money/topstocks/moonlake-immunotherapeutics-announces-150m-public-offering/ar-AA26hNDW?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-24T07:10:37", "published_display": "24 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering", "summary": "MoonLake Immunotherapeutics announced the pricing of an upsized public offering expected to raise approximately $200 million. The offering includes 9,000,000 Class A ordinary shares at $20.00 each and pre-funded warrants for an additional 1,000,000 Class A ordinary shares. Procee", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316568/0/en/moonlake-immunotherapeutics-announces-pricing-of-upsized-200-million-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T03:11:07", "published_display": "24 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants", "summary": "MoonLake Immunotherapeutics announced the pricing of a public offering of 9,000,000 Class A ordinary shares at $20.00 each, and pre-funded warrants for an additional 1,000,000 shares at $19.9999 each, aiming to raise approximately $200 million. The proceeds will fund the research", "url": "https://www.quiverquant.com/news/MoonLake+Immunotherapeutics+Prices+$200+Million+Public+Offering+of+Class+A+Ordinary+Shares+and+Pre-Funded+Warrants", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T03:10:00", "published_display": "24 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moonlake Immunotherapeutics Insider Sold Shares Worth $862,205, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/moonlake-immunotherapeutics-insider-sold-shares-201152243.html", "source_name": "MT Newswires", "published_at": "2026-06-23T20:11:52+00:00", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) CFO sells 39,120 shares in open-market trade", "summary": "MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, sold 39,120 Class A ordinary shares on June 22, 2026, at a weighted average price of $22.04 per share. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, represents a small port", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-285362a1846b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:40:46", "published_display": "23 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher (NASDAQ:MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYXBYMzJOakJIcEMxZXhqcUdzUHQ3cEhkbmtzZGZxRGFhd1FhR3BCMFNhQjl2T0E3OWNKMG15aHdHQW5KV2FYai11Ulo1OEVBU3JQYmNWNHRzazZVNkN2WnMwUFNhZHp4UHFMOEQ5RGJ4UkNwbmV6VngyRy1sNDZjZTJILXFKWlVZLXVQRjllaUp0SUdoM01OdFY3Vzh5N1E3dG9HUVJYUVAtRXVl?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics | 424B5: Prospectus", "summary": "MoonLake Immunotherapeutics has announced a public offering of Class A Ordinary Shares and pre-funded warrants aiming for gross proceeds of $150 million. The offering price for Class A Ordinary Shares is $22.16, matching the last Nasdaq Capital Market sale price. The company plan", "url": "https://www.moomoo.com/news/notice/307570297/moonlake-immunotherapeutics-424b5-prospectus", "source_name": "Moomoo", "published_at": "2026-06-23T01:40:50", "published_display": "23 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) seeks $150M via offering", "summary": "MoonLake Immunotherapeutics is conducting a public offering to raise $150 million through the sale of Class A Ordinary Shares and pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to advance the research, development, and potential comme", "url": "https://www.stocktitan.net/sec-filings/MLTX/424b5-moon-lake-immunotherapeutics-prospectus-supplement-debt-securit-f32b27f1cfbe.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:11:27", "published_display": "22 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake seeks $150M in stock sale to fund sonelokimab work", "summary": "MoonLake Immunotherapeutics (NASDAQ: MLTX) announced a proposed public offering of $150 million in Class A ordinary shares and pre-funded warrants. The proceeds are intended to fund the development and potential commercialization of sonelokimab, as well as for general corporate p", "url": "https://www.stocktitan.net/news/MLTX/moon-lake-immunotherapeutics-announces-proposed-public-nat61jm979b9.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:27", "published_display": "22 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake\u2019s HS drug posts 67% HiSCR75 at Week 52", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPREUzM1BEanNUMjZsdU1RTDl6elA0N1Rsc3dkdnlZU2t2TktxdzlkNXdIMUhzUXdiSGFuTk9iWHlKWHRXX1BUVlF6dXJxQ2FKZGczS29mMi1hbHhFZ3lsWHRiREVZdDU3YVVkTnJlTHI5NUFobkZ3SDZDTTdBOV9FaVJSWTVyWVZjaU9HWURSMWhyU3RiZnBNalRITEZtRXpTYmpCTFo4QmExVG51em5ndDZWb3R4MTlyTmNDX29KTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) director receives 22,195 stock options grant", "summary": "MoonLake Immunotherapeutics director Catherine Moukheibir was granted 22,195 options to purchase Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. These options will vest in full on the earlier of June 17, 2027, or the co", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-2f17d4cc6445.html", "source_name": "Stock Titan", "published_at": "2026-06-18T23:09:48", "published_display": "18 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) director granted options on 22,195 shares", "summary": "MoonLake Immunotherapeutics director Andrew John Phillips has been granted stock options for 22,195 Class A ordinary shares, with an exercise price of $19.19 per share. These options will vest in full either on June 17, 2027, or at the company's next annual general meeting, conti", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-9647adaced08.html", "source_name": "Stock Titan", "published_at": "2026-06-18T23:09:48", "published_display": "18 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOaTBBYWlRckhXYjhxckRZNDVzZXFPRmJuRzBWMGlsWVpmTFBpYjNaXzFFVXBDQUFmNjBiM3BLeWM1anh3RVM5eGliSGlLSkh5LUNlZUFqTThHRFh4TGcxNGJCTGhOU1NRYlk4dkJlZ0tWbFg5VW5yTGdIQVNjQjNmWnBIWGg1c3h3ZFdNdFpiZkRRTnZrd29zdUw5TzBfNDlHOE1hQ1d3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxNTDBHR3BIdWIzV284YnBMSmZvLVd3YnFZblpsRTFkbU5oMmNrd2JWV0tja2FKdy1xNGg4dzV4ZkxzRkU0clVMV1lHU0FoRUtaaTR5MzZERlNINUFCZzdSUGUxeDVCRFYtWF9DQ18tUG1BQVpOV010YnVvWHFhR3pCcDI5NkI4Z25IaWx3ak0za3ZxRFVtUDBMSl9LUzg3VE5UbGV6NTZ2cHpmdER4RldoZXJyYTdqNEZlU3FaNjhzNEh0WUMxUmZrVjNzVDFKdFdKLWJRYWN0TDNfX2NsRDNzVHlZY0NVZTRyOGtLVFM2bkxpbnVhY201RUFJRE5Pd2ZZVWhweWUwejB5dmJHQlpjdFA2SjdaN3VjaTd6M3hmeDQtR0Q5eDdaQ3dtbmh0cFNUc05sdkFaeHY2Z3JITmRQMEIwQVNMdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Have Insiders Sold MoonLake Immunotherapeutics Shares Recently?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdU01dEU2VnBtNmhTby1sTU12TkVyQlROUTcwbDh2UHFZeGhwOXViZmZjX2ZjUTNGQmpHTVduaVRtT19RQjJDa0IyeDJndzJYOG5kMFhrcUpHWWVveEt4eDZpbXFjVUlqelo4dW1fVGgyak5fNG5yTlZsbl9VQmloYjE2ZG9IQ0I0V21iRDk5dkNNcjNFWk9fOXlwelB5ZjZXVXRhYXVZVHRiVk81Y1N3LXZDMkpQUDRSSjJJci1YS1BqMEFBZkMzNXNhanYwUGZ5YldVWk5OTGhwTzluQ2pJR2xFSFJSTWFPcGhvVmRRcjZ5Mm_SAfgBQVVfeXFMT0dEMEMyNkN1MVh6dUtNM3VfcGVIQm96SUFDcVpLWktrUkVGVUdWVThVWlp2c01PRkZhX25xUUNwMVFhbW9aV192ZTNlY3J0enFTTkk3bkZtajIyVWtyWksxLWJheTUxeGMxd1I4Rk1ldExocGV6c0lQUERpZnBaRmd6bk13dENseWdOZ25oQ28xR2Z1cVc2RlFDdkRabVdiZDNOLUpGQW9POW9PRFBBczUxSEhOR3h1U2ZSVzZxYmgzd1JZZU5PVHAySjZnSnpRV0FDU3Rqc0RzcVFDbkpfd3E0U1hOTWRQWGdKaXJXWXA3cG1VLTJESm8?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQmpCREZWenV2RVk4TF9FUFRWUGw5OUFHMWNjNG1TSHB1QUU3RmJjbUlUVjJQQzl3OGpPSTY0cWNhSi1mSmhHYjdNVHBLakI2OERNaUVSVmJ2Z0dZYVNWQVhmd1JMdlNIMEEwa0g2YU1jMFc0ZzNCS0FabVFmTGNtVExEZ0hGVkx0WU9RZmhNeTYyMjUtbDJFd0tQRWVtdVJHS3lsem9ycVdwcjk2M3d5VU9GOUFEUFNHSVo1T0ZzTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday\u2019s Plunge: Retail Sees Significant Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNV0lHNTNuMFJnVlNXUER2ZVpPV3R2Sk55NXFSQnoybVpIMUx6ZjM4TVI4dm1pLXJIbDRRZ2psaEVVYVAwRVliaWlhX3liR05zOHNNYlY5UjFFY2puSFg1SlIxTklubGlkVFE4VThDVmE0Q1hYbGpBaE9DSmpmWVNVWjg5UGY2cnluS0xVVTVqZkFFQ3hnUFYtQ2R4dFJCdWZnSjJ4aUxvTjI3NS1aMVRsTDdzZDUyM2xJeVp0aGo1dk5ZQ1R6am4tN3Uybzg4cFZGOTloRENXbm93YTQyWFE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake\u2019s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioTech Breakout: MoonLake Up 30% On FDA Wins", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPb2dINnI5LXpuZkZnTS1WMWlPbWE4THdSZzFkbk9ZM1k1Ni05RVk2R244V0pmek40VmFURUhKNnhfS0xEa2dqWnpBYUc1dUtVR0VUM21WSjJrRDN5Q0I4TjNMZ1AtQ3BHVGxHWkpEYlFmWkhjdnRlSUl6NGREamtpRXBWNGtUdG8?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Fast Tracks MoonLake drug for severe palmoplantar pustulosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQal82eWMyZ3B3ZkFaVHV1aDRZbG1VOUhmakhtNGp6UzV1bVQ0cTZwMDBmLVc1TmpuMzZKUWpvMGxjQ1gtSWp3bzJWbmZDSU1oUGszVTNSM1dKTzlLTms0ZmwyTVVIT0o1M2V3dkk2Mm8yRmVyWTN0Vld0dnczNGctQmRraGtEVy1DMVByZEZMUXdZMTY4QXRfaDlzUGpVekJvaVE1SUlIV1dzY0NFY2VWT2E0bElSQ3Vn?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPLTZ6WmM0U2M2TnJzX1ZIeTlLNks1aXFlUjVEV3RGSjJKTTJzN2YtZHRFd2ZkWlBleENoV1AxeDlRYU85VndSNEQteWxROEwxNjFRaVVGN3Y1TXpDWVZkQVVLNjh2TXcwVzJib2FKYmhhUjBfSUg3N21KVllQYUhKeUtkTmJ4bXhLVm1YMmxGMm5uOHV5c3ROdE9sTkl1bW9XYUE?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNEtNMTRHMHZBb2RadXVlOWhUTDlidk8wMG1udVBmWVFDSHdVOGttVy00VWxqdlBjV21ZQ1dFVDQ5OWJFYklWRWZiWjZpb3E0SzdqUzBDWDVTSWlHY3RRZzFGbTAwVTJ1WEtXWEZlZnY2U1VNcHhLREhfS1NtYUNzU2gxcTZTaEN3dkROYzByWkZjakN6aF8yZVljdzhaVTl0UjR3VTc3Skc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:47:09+00:00", "published_display": "15 Jul 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise", "summary": "MoonLake Immunotherapeutics announced that underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares as part of a previously announced public offering. This exercise, which closed on July 14, 2026, generated an additional $30.0 million ", "url": "https://www.stocktitan.net/sec-filings/MLTX/8-k-moon-lake-immunotherapeutics-reports-material-event-858ab2e59057.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:11:17", "published_display": "15 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of MoonLake Immunotherapeutics (MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxQT09MN2NQNDh1WFBrUmVUMkJ2b2dQYnRYRllqcDBnYzMwYzNmbjVqNEI1RXVCTmlxTWp4ejlaZk90aE9MMVFpcl9oWVVJTmtlTDZWLUpGYURmelhOOE5HOUJGc3JSTkRyd19SeVk4TzVjdkxnbml5X21YeFVzWU9DWXU3Wk43YzZHTWtoTXIwdWY1WXFKRzc5MFl4ei1BTTltM0ctMDVPaktXeGFEMmVUYzBpdk9acGxqRVlFLTh0R0JSaUpGRUdKZzRtUDdzMGZjYmpMZ2F4eUJFdk9tRjd4U19fZjNOd2xQaUhNbTRrblowZEdtV3FPZmJqQXh3QQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T09:26:48+00:00", "published_display": "14 Jul 2026 09:26", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZkVHa3l5SEF6dW9vM1RCS1ZqckR5enZVMHRxWjVnR0FDTE52VUlKWW40RXVKa0xra2pTemlhbXBodjVUWFFMemJCRXRIWjVNZFkzUXNRQjJncHZRT1NCZUNiQkdnaWJGRndFY1RZLTZBLVdhVG5SSzhVdXFNbk9LWHlHenZKdjVGOHplX3VUdjdLSG50c29fcVJzWkN0SmwwQ0d0UldpbnQxUTQ3SVNyLXFBUU5LVDQ4TVg5Ui1lQTRoRWY4OVR6UlEzVkhGZmc?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T06:55:22+00:00", "published_display": "14 Jul 2026 06:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MoonLake Immunotherapeutics Insider Trading Activity", "summary": "MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 102,225 Class A ordinary shares in open market transactions on July 9 and 10, 2026. The sales, totaling approximately $2.05 million, were made under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, S", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-f1f6911c9177.html", "source_name": "Stock Titan", "published_at": "2026-07-13T19:42:00", "published_display": "13 Jul 2026 19:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Dip As Trump-Iran Tensions Lift Crude Oil Prices: Why MU, MRAM, MLTX, DRTS, ASTS Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNTHI0dUdheHljRkpJZlZiZURTX0x6TDAwZFNNdWVmUW0ya0tENzJYMkVjYkEwUGpGOW9TUkZRX2xma3ZGYy1xU2RqT1JKVjVaMUVVU1U0bmUtWFh0cVJUNUdoYjR5QUNybEVkVndCY2NNSUtfM1dUcUlQSFQwUVp4UXJWTWpMN1JsYTR2Nm5rRXJ4V08zSnFkdk1zcVNTMWVPdHdKUG1BaTZOa3JwdklSUGtZRUtYb0twUlEySlZhWHFFVHVldmt0S2FCMXQ3LTg?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T15:08:28+00:00", "published_display": "13 Jul 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan", "summary": "The CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX), Jorge Santos da Silva, sold 47,775 Class A ordinary shares at a weighted average price of $20.03 per share on July 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 202", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-7c16db97488b.html", "source_name": "Stock Titan", "published_at": "2026-07-03T16:39:20", "published_display": "03 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics' CFO Sells 39K Shares", "summary": "", "url": "https://finance.yahoo.com/m/e2ea9480-3335-3987-851b-a172c41d9171/moonlake-immunotherapeutics%27.html", "source_name": "Motley Fool", "published_at": "2026-07-03T14:34:01+00:00", "published_display": "03 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX) \u2013 Recover Losses - Contact Levi & Korsinsky Before December 15, 2025", "summary": "A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made fals", "url": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-against-moonlake-immunotherapeutics-mltx-0", "source_name": "The National Law Review", "published_at": "2026-07-02T12:40:51", "published_display": "02 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026)", "summary": "MoonLake Immunotherapeutics (MLTX) has filed a Rule 144 notice indicating a proposed resale of 150,000 Class A Ordinary shares. The filing specifies a contemporaneous sale of these shares by Jorge Santos da Silva on April 10, 2026, for $2,787,000.00. The shares are listed on Nasd", "url": "https://www.stocktitan.net/sec-filings/MLTX/144-moon-lake-immunotherapeutics-sec-filing-be5d4a3abe72.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:11:22", "published_display": "01 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPai1ZcnNDYmk3WHFjS3ZHS2NzYmpHTzlWMjV0cV9lNk5XMmVVRE1ERGtLbFNHRUtBY3pzSEdJQnJnRnJJMmlKTG9OS2x3a0xpaHpJclRXVjRYTlFVeW4ycDIwUkhZMXlIZ0xLWVFNM3d3NWxsdDVDTjFCc2dDQVgycmxjVjAzd0RwQUZqN2h6QlJTWTVtQUtjRy1zR3FoYVBfTU1ISl9TMmpTTmdiNHBma1Bldw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake", "summary": "BVF group has updated its ownership disclosure in MoonLake Immunotherapeutics (MLTX) through an Amendment No. 6 to its Schedule 13D. The filing indicates that BVF-affiliated funds beneficially own 16,001,284 Class A ordinary shares, representing approximately 19.7% of MoonLake's ", "url": "https://www.stocktitan.net/sec-filings/MLTX/schedule-13d-a-moon-lake-immunotherapeutics-amended-major-shareholder-3ca86f17b419.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:09:32", "published_display": "30 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1IQjQwZm4wQlZjSUQyVlYzOWxMeGYxeTVmWFpTd3pfUjN3dGdRZ2txMDJ4aHN1QlRfMHByQXZYdXZYN1oxOUFuN2syVzdfa2lqSkwxaEdtRjRfMWJZanBxUjhnTzM?oc=5", "source_name": "ChartMill", "published_at": "2026-06-29T17:39:03+00:00", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab Push - Has The Bull Case Changed?", "summary": "MoonLake Immunotherapeutics (MLTX) recently raised $200 million through a follow-on equity offering to fund its sonelokimab program, particularly for the planned Biologics License Application (BLA) in hidradenitis suppurativa and pre-commercial activities. This capital raise, fol", "url": "https://www.sahmcapital.com/news/content/moonlake-immunotherapeutics-mltx-is-down-102-after-200m-follow-on-offering-to-fund-sonelokimab-push-has-the-bull-case-changed-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-29T17:09:05", "published_display": "29 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares", "summary": "MoonLake Immunotherapeutics (NASDAQ: MLTX) has successfully completed a $200 million public offering of its Class A shares. The offering involved legal advisory from Gibson, Dunn & Crutcher LLP and Walkers (Cayman) LLP for MoonLake, while Mintz, Levin, Cohn, Ferris, Glovsky, and ", "url": "https://globallegalchronicle.com/post-236054/", "source_name": "Global Legal Chronicle", "published_at": "2026-06-29T14:39:49", "published_display": "29 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (MLTX) for alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements about the purported superiority of it", "url": "https://natlawreview.com/press-releases/lost-money-moonlake-immunotherapeutics-mltx-join-class-action-december-15", "source_name": "The National Law Review", "published_at": "2026-06-28T17:10:20", "published_display": "28 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX)", "summary": "This article provides an overview of MoonLake Immunotherapeutics (NASDAQ: MLTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial information such as past earnings and revenue, upcoming earnings dat", "url": "https://www.tradingview.com/symbols/NASDAQ-MLTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:32", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United States - Mintz Advises On MoonLake Immunotherapeutics\u2019 $200 Million Public Offering", "summary": "Mintz advised the underwriters for MoonLake Immunotherapeutics' $200 million public offering of Class A ordinary shares. Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital served as joint bookrunning managers, with H.C. Wainwright & Co. and Clear Street as lead ", "url": "https://www.mondaq.com/pressrelease/200328/mintz-advises-on-moonlake-immunotherapeutics-%24200-million-public-offering", "source_name": "Mondaq", "published_at": "2026-06-26T03:41:09", "published_display": "26 Jun 2026 03:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (BOATS:MLTX)", "summary": "This article provides an overview of MoonLake Immunotherapeutics (MLTX) stock, including financial actuals and analyst estimates. It details the company's valuation metrics, past financial performance, future earnings projections, and historical stock prices. Key financial figure", "url": "https://www.tradingview.com/symbols/BOATS-MLTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:20", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Class A Actuals & Estimates (BIVA:MLTX/N)", "summary": "This article provides financial actuals and estimates for MoonLake Immunotherapeutics Class A (MLTX/N) traded on BIVA exchange, including market cap, earnings reports, revenue, and net income. It also details analysts' price targets, stock volatility, and employees. The company's", "url": "https://www.tradingview.com/symbols/BIVA-MLTX/N/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T00:41:09", "published_display": "26 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MLTX/N Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for MoonLake Immunotherapeutics Class A (MLTX/N) stock, including analyst price targets, ratings, and financial metrics. It highlights that 14 analysts offer 1-year price forecasts, and outlines the company's past earnings, revenue, and market cap", "url": "https://www.tradingview.com/symbols/BIVA-MLTX/N/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:09", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWnlHUlBlazhib29ubDFMNEZBaDdFX1FZbVZhdjlGVGVSQVhVZGxKQ1ZhZDgwQjJZWjlVX3pGOHFKNzl5bjhUaWx3ZTYtSklNN3NkLTUzTzBVQzFRZnVISGp5OXBLVXVKd1JUN3BnQzdtTVFsa0gtbXk1U0h5Q1pwMllEQVlybFlDWkFkS2pxbG4teFFOUkpfeExaZjk4OWF2RF9Bb3ZwOFhsQk5ZNThNY1RObmU?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) launches $200M equity and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPM0RXWTJ5RjhqYmdHOUZVSGtYMmV0SEQ5SVlnQ1AxRGdVdXhBSVprcFVrd2lyak16cktmMEhRWjRiczhmLVlOWlVfblhYVDlHX2ZIaWl4RUFENzVWcE11cDVMRmpOSl9MUjR1NG1iZ1E2QXRfcl8tRFNYOGljZnVDRV9lWTctelNxMjd2UEFlOFo5c1NtVFlzTVI0dlpDQjhueGhmNFpYYldIYUd3NnNRbHdob1FjVnBG?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Proposed Public Offering", "summary": "MoonLake Immunotherapeutics has announced a proposed public offering of $150 million of its Class A ordinary shares, and potentially pre-funded warrants, to fund the development and commercialization of its investigational drug sonelokimab. The company also expects to grant under", "url": "https://uk.finance.yahoo.com/news/moonlake-immunotherapeutics-announces-proposed-public-200100398.html", "source_name": "Market source", "published_at": "2026-06-25T03:39:09", "published_display": "25 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-prices-200-million-073356678.html", "source_name": "MT Newswires", "published_at": "2026-06-24T07:33:56+00:00", "published_display": "24 Jun 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics prices $200M public offering to fund inflammatory disease drug development", "summary": "MoonLake Immunotherapeutics has priced a $200 million public offering, selling 9 million Class A shares at $20 each, along with pre-funded warrants. The funding is intended to advance the development and commercialization of sonelokimab, a drug for inflammatory diseases like hidr", "url": "https://pluang.com/en/news-feed/moonlake-immunotherapeutics-mengumumkan-penawaran-publik-200-juta-dolar", "source_name": "Pluang", "published_at": "2026-06-24T08:11:07", "published_display": "24 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why MoonLake Immunotherapeutics Stock Wilted on Wednesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVzJYVEJRTU9neURTNUVjTThmQzgwY0pyZnNaUFpQTmRpNzBLcnU0VWFDalp1VlhSRDhBNFBXa3V0R3FDUFBxZGlYV2ZOa29FcFNfMF9sNVdkR3NGaXQ0T1dUb252cXczT0NOWFZyZmEtY2JRZTJYaWxsbkNKQm5kSktBQlAzUjZEaTJFNHIzMHRKRDNqQXVPVw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) On Phase 3 Data While A 6x P B Valuation Looks Pricey", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) offers 9M shares at $20; 1M pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNRUZtTTBKUFhZM3I1cXJhZ2JuaFV2NGlKaXhDQ1FkNFQ4MTJpaDY4Vk1ZLUR0SXJKdXlIOWJYVHM5dGhWOTJscWhDTTJ4M3NEZVpqal9iOE56cFU2WTM4MDBUYm01RWgzOUVOUy0wdTAtZmNfQmU2Ni1ZRnJtS3JJSUxTYVhjT1N1TGRMMWJyUFNELWNoOENLbEZMdXlaaE5HblJ1SmtjZGZCZjVRa0piT19ZUnF1TFpmYVVWbmdhRkFDNEExWm5tSjBiaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants | MLTX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQZGtHZlBqX09IR0xEYkREZXNKVjBFTE5GS01PejhSYkVCT0R5VkVvRDNsbFVEb01MY2JBNkZmeDluLXl6WHFrX0lIeGxqYk1JU01qQ1ljaHVGTWFWa090WWtSUnFScE0wQW5ERjYzU2V4Q250S1Y0MnIzdEhkX280czNFQ2xmeWFIekxDRnItd2huM29wZ3Y1SDdqaEtLQW4zWmZ5czdVZ2hKVDh5TDZiV2d0MmEyaW1rd3dhNVFMU0Z1ZGhFcndqY2lOcEkyMXRpeDFUQTBfbHVRN2dYMTk5VDBTOA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake seeks $200M to fund sonelokimab work", "summary": "MoonLake Immunotherapeutics has priced an upsized underwritten public offering to raise approximately $200 million in gross proceeds. The funds, combined with existing cash, are intended to finance the research, development, and potential commercialization of sonelokimab, a novel", "url": "https://www.stocktitan.net/news/MLTX/moon-lake-immunotherapeutics-announces-pricing-of-upsized-200-p76858wi6hqx.html", "source_name": "Stock Titan", "published_at": "2026-06-24T07:11:07", "published_display": "24 Jun 2026 07:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics announces $150M public offering", "summary": "MoonLake Immunotherapeutics has announced a public offering aimed at raising $150 million. The company is involved in the biotechnology sector, focusing on immunotherapeutics. This offering is likely intended to fund ongoing research, clinical trials, or general corporate purpose", "url": "http://www.msn.com/en-us/money/topstocks/moonlake-immunotherapeutics-announces-150m-public-offering/ar-AA26hNDW?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-24T07:10:37", "published_display": "24 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering", "summary": "MoonLake Immunotherapeutics announced the pricing of an upsized public offering expected to raise approximately $200 million. The offering includes 9,000,000 Class A ordinary shares at $20.00 each and pre-funded warrants for an additional 1,000,000 Class A ordinary shares. Procee", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316568/0/en/moonlake-immunotherapeutics-announces-pricing-of-upsized-200-million-public-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T03:11:07", "published_display": "24 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants", "summary": "MoonLake Immunotherapeutics announced the pricing of a public offering of 9,000,000 Class A ordinary shares at $20.00 each, and pre-funded warrants for an additional 1,000,000 shares at $19.9999 each, aiming to raise approximately $200 million. The proceeds will fund the research", "url": "https://www.quiverquant.com/news/MoonLake+Immunotherapeutics+Prices+$200+Million+Public+Offering+of+Class+A+Ordinary+Shares+and+Pre-Funded+Warrants", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T03:10:00", "published_display": "24 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moonlake Immunotherapeutics Insider Sold Shares Worth $862,205, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/moonlake-immunotherapeutics-insider-sold-shares-201152243.html", "source_name": "MT Newswires", "published_at": "2026-06-23T20:11:52+00:00", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) CFO sells 39,120 shares in open-market trade", "summary": "MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, sold 39,120 Class A ordinary shares on June 22, 2026, at a weighted average price of $22.04 per share. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, represents a small port", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-285362a1846b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:40:46", "published_display": "23 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher (NASDAQ:MLTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOYXBYMzJOakJIcEMxZXhqcUdzUHQ3cEhkbmtzZGZxRGFhd1FhR3BCMFNhQjl2T0E3OWNKMG15aHdHQW5KV2FYai11Ulo1OEVBU3JQYmNWNHRzazZVNkN2WnMwUFNhZHp4UHFMOEQ5RGJ4UkNwbmV6VngyRy1sNDZjZTJILXFKWlVZLXVQRjllaUp0SUdoM01OdFY3Vzh5N1E3dG9HUVJYUVAtRXVl?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics | 424B5: Prospectus", "summary": "MoonLake Immunotherapeutics has announced a public offering of Class A Ordinary Shares and pre-funded warrants aiming for gross proceeds of $150 million. The offering price for Class A Ordinary Shares is $22.16, matching the last Nasdaq Capital Market sale price. The company plan", "url": "https://www.moomoo.com/news/notice/307570297/moonlake-immunotherapeutics-424b5-prospectus", "source_name": "Moomoo", "published_at": "2026-06-23T01:40:50", "published_display": "23 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) seeks $150M via offering", "summary": "MoonLake Immunotherapeutics is conducting a public offering to raise $150 million through the sale of Class A Ordinary Shares and pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to advance the research, development, and potential comme", "url": "https://www.stocktitan.net/sec-filings/MLTX/424b5-moon-lake-immunotherapeutics-prospectus-supplement-debt-securit-f32b27f1cfbe.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:11:27", "published_display": "22 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake seeks $150M in stock sale to fund sonelokimab work", "summary": "MoonLake Immunotherapeutics (NASDAQ: MLTX) announced a proposed public offering of $150 million in Class A ordinary shares and pre-funded warrants. The proceeds are intended to fund the development and potential commercialization of sonelokimab, as well as for general corporate p", "url": "https://www.stocktitan.net/news/MLTX/moon-lake-immunotherapeutics-announces-proposed-public-nat61jm979b9.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:27", "published_display": "22 Jun 2026 20:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake\u2019s HS drug posts 67% HiSCR75 at Week 52", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPREUzM1BEanNUMjZsdU1RTDl6elA0N1Rsc3dkdnlZU2t2TktxdzlkNXdIMUhzUXdiSGFuTk9iWHlKWHRXX1BUVlF6dXJxQ2FKZGczS29mMi1hbHhFZ3lsWHRiREVZdDU3YVVkTnJlTHI5NUFobkZ3SDZDTTdBOV9FaVJSWTVyWVZjaU9HWURSMWhyU3RiZnBNalRITEZtRXpTYmpCTFo4QmExVG51em5ndDZWb3R4MTlyTmNDX29KTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) director receives 22,195 stock options grant", "summary": "MoonLake Immunotherapeutics director Catherine Moukheibir was granted 22,195 options to purchase Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. These options will vest in full on the earlier of June 17, 2027, or the co", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-2f17d4cc6445.html", "source_name": "Stock Titan", "published_at": "2026-06-18T23:09:48", "published_display": "18 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (MLTX) director granted options on 22,195 shares", "summary": "MoonLake Immunotherapeutics director Andrew John Phillips has been granted stock options for 22,195 Class A ordinary shares, with an exercise price of $19.19 per share. These options will vest in full either on June 17, 2027, or at the company's next annual general meeting, conti", "url": "https://www.stocktitan.net/sec-filings/MLTX/form-4-moon-lake-immunotherapeutics-insider-trading-activity-9647adaced08.html", "source_name": "Stock Titan", "published_at": "2026-06-18T23:09:48", "published_display": "18 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOaTBBYWlRckhXYjhxckRZNDVzZXFPRmJuRzBWMGlsWVpmTFBpYjNaXzFFVXBDQUFmNjBiM3BLeWM1anh3RVM5eGliSGlLSkh5LUNlZUFqTThHRFh4TGcxNGJCTGhOU1NRYlk4dkJlZ0tWbFg5VW5yTGdIQVNjQjNmWnBIWGg1c3h3ZFdNdFpiZkRRTnZrd29zdUw5TzBfNDlHOE1hQ1d3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgJBVV95cUxNTDBHR3BIdWIzV284YnBMSmZvLVd3YnFZblpsRTFkbU5oMmNrd2JWV0tja2FKdy1xNGg4dzV4ZkxzRkU0clVMV1lHU0FoRUtaaTR5MzZERlNINUFCZzdSUGUxeDVCRFYtWF9DQ18tUG1BQVpOV010YnVvWHFhR3pCcDI5NkI4Z25IaWx3ak0za3ZxRFVtUDBMSl9LUzg3VE5UbGV6NTZ2cHpmdER4RldoZXJyYTdqNEZlU3FaNjhzNEh0WUMxUmZrVjNzVDFKdFdKLWJRYWN0TDNfX2NsRDNzVHlZY0NVZTRyOGtLVFM2bkxpbnVhY201RUFJRE5Pd2ZZVWhweWUwejB5dmJHQlpjdFA2SjdaN3VjaTd6M3hmeDQtR0Q5eDdaQ3dtbmh0cFNUc05sdkFaeHY2Z3JITmRQMEIwQVNMdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold MoonLake Immunotherapeutics Shares Recently?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdU01dEU2VnBtNmhTby1sTU12TkVyQlROUTcwbDh2UHFZeGhwOXViZmZjX2ZjUTNGQmpHTVduaVRtT19RQjJDa0IyeDJndzJYOG5kMFhrcUpHWWVveEt4eDZpbXFjVUlqelo4dW1fVGgyak5fNG5yTlZsbl9VQmloYjE2ZG9IQ0I0V21iRDk5dkNNcjNFWk9fOXlwelB5ZjZXVXRhYXVZVHRiVk81Y1N3LXZDMkpQUDRSSjJJci1YS1BqMEFBZkMzNXNhanYwUGZ5YldVWk5OTGhwTzluQ2pJR2xFSFJSTWFPcGhvVmRRcjZ5Mm_SAfgBQVVfeXFMT0dEMEMyNkN1MVh6dUtNM3VfcGVIQm96SUFDcVpLWktrUkVGVUdWVThVWlp2c01PRkZhX25xUUNwMVFhbW9aV192ZTNlY3J0enFTTkk3bkZtajIyVWtyWksxLWJheTUxeGMxd1I4Rk1ldExocGV6c0lQUERpZnBaRmd6bk13dENseWdOZ25oQ28xR2Z1cVc2RlFDdkRabVdiZDNOLUpGQW9POW9PRFBBczUxSEhOR3h1U2ZSVzZxYmgzd1JZZU5PVHAySjZnSnpRV0FDU3Rqc0RzcVFDbkpfd3E0U1hOTWRQWGdKaXJXWXA3cG1VLTJESm8?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQmpCREZWenV2RVk4TF9FUFRWUGw5OUFHMWNjNG1TSHB1QUU3RmJjbUlUVjJQQzl3OGpPSTY0cWNhSi1mSmhHYjdNVHBLakI2OERNaUVSVmJ2Z0dZYVNWQVhmd1JMdlNIMEEwa0g2YU1jMFc0ZzNCS0FabVFmTGNtVExEZ0hGVkx0WU9RZmhNeTYyMjUtbDJFd0tQRWVtdVJHS3lsem9ycVdwcjk2M3d5VU9GOUFEUFNHSVo1T0ZzTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday\u2019s Plunge: Retail Sees Significant Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNV0lHNTNuMFJnVlNXUER2ZVpPV3R2Sk55NXFSQnoybVpIMUx6ZjM4TVI4dm1pLXJIbDRRZ2psaEVVYVAwRVliaWlhX3liR05zOHNNYlY5UjFFY2puSFg1SlIxTklubGlkVFE4VThDVmE0Q1hYbGpBaE9DSmpmWVNVWjg5UGY2cnluS0xVVTVqZkFFQ3hnUFYtQ2R4dFJCdWZnSjJ4aUxvTjI3NS1aMVRsTDdzZDUyM2xJeVp0aGo1dk5ZQ1R6am4tN3Uybzg4cFZGOTloRENXbm93YTQyWFE?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake\u2019s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioTech Breakout: MoonLake Up 30% On FDA Wins", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPb2dINnI5LXpuZkZnTS1WMWlPbWE4THdSZzFkbk9ZM1k1Ni05RVk2R244V0pmek40VmFURUhKNnhfS0xEa2dqWnpBYUc1dUtVR0VUM21WSjJrRDN5Q0I4TjNMZ1AtQ3BHVGxHWkpEYlFmWkhjdnRlSUl6NGREamtpRXBWNGtUdG8?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Fast Tracks MoonLake drug for severe palmoplantar pustulosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQal82eWMyZ3B3ZkFaVHV1aDRZbG1VOUhmakhtNGp6UzV1bVQ0cTZwMDBmLVc1TmpuMzZKUWpvMGxjQ1gtSWp3bzJWbmZDSU1oUGszVTNSM1dKTzlLTms0ZmwyTVVIT0o1M2V3dkk2Mm8yRmVyWTN0Vld0dnczNGctQmRraGtEVy1DMVByZEZMUXdZMTY4QXRfaDlzUGpVekJvaVE1SUlIV1dzY0NFY2VWT2E0bElSQ3Vn?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPLTZ6WmM0U2M2TnJzX1ZIeTlLNks1aXFlUjVEV3RGSjJKTTJzN2YtZHRFd2ZkWlBleENoV1AxeDlRYU85VndSNEQteWxROEwxNjFRaVVGN3Y1TXpDWVZkQVVLNjh2TXcwVzJib2FKYmhhUjBfSUg3N21KVllQYUhKeUtkTmJ4bXhLVm1YMmxGMm5uOHV5c3ROdE9sTkl1bW9XYUE?oc=5", "source_name": "Market source", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 61, "sentiment_summary": {"positive": 12, "negative": 9, "neutral": 40, "score": 50, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 23.45, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 20.36, "latest_week": "2026-07-10", "one_week_move": 7.4, "four_week_move": 8.9, "twelve_week_move": 11.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.498726, "market_dynamics_buy_signal": false, "relative_strength": -29.355067, "fair_value_gap": -49.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.9486, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.4% over one week, +8.9% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Stocktwits", "count": 3}, {"label": "The National Law Review", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.4% over one week, +8.9% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)"}], "updated_at": "2026-07-16T02:02:43.588950+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}